

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Ocumention Therapeutics
歐康維視生物

(Incorporated in the Cayman Islands with limited liability)

(Stock code: 1477)

**CHANGE OF JOINT COMPANY SECRETARIES AND
AUTHORIZED REPRESENTATIVE**

The board of directors (the “**Board**”) of Ocumention Therapeutics (the “**Company**”, together with its subsidiaries, the “**Group**”) announces that (i) due to personal reasons, Ms. Yun JI (“**Ms. JI**”) has tendered her resignation as a joint company secretary of the Company (the “**Joint Company Secretary**”), and will cease to act as a Joint Company Secretary with effect from September 30, 2023; and (ii) Ms. CHAU Hing Ling (“**Ms. CHAU**”) has tendered her resignation as (a) a Joint Company Secretary, and (b) an authorized representative of the Company pursuant to Rule 3.05 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”) (the “**Authorized Representative**”), and will cease to act as a Joint Company Secretary and an Authorized Representative with effect from September 30, 2023.

Each of Ms. JI and Ms. CHAU has confirmed that she has no disagreement with the Board and there is no matter relating to her resignation that needs to be brought to the attention of the shareholders of the Company or the Stock Exchange.

Following the cessation of Ms. JI and Ms. CHAU to act as a Joint Company Secretary, respectively, the Board is pleased to announce that (i) Mr. Tim RUAN (阮添士) (“**Mr. RUAN**”) and Ms. Tingchan CHEN (陳聽蟬) (“**Ms. CHEN**”) have been appointed as Joint Company Secretaries in place of Ms. JI and Ms. CHAU with effect from September 30, 2023; and (ii) Mr. RUAN has been appointed as an Authorized Representative in place of Ms. CHAU with effect from September 30, 2023.

The biographical details of Mr. RUAN and Ms. CHEN are set out below:

MR. RUAN

Mr. RUAN, aged 37, has been our chief financial officer since January 12, 2023, responsible for financial management and investor relations of the Group. Mr. RUAN has extensive experience of financial management. Prior to joining our Group, he served as an executive director of the investment banking division of Goldman Sachs (Asia) L.L.C. from November 2020 to January 2023, primarily responsible for affairs in debt and equity capital markets and M&A. From January 2018 to November 2020, he served as a vice president of the investment banking division of Morgan Stanley Asia Limited. From February 2016 to January 2018, he acted as an associate within the investment banking division of Nomura International (Hong Kong) Limited. From September 2013 to January 2016, he served as associate at Sullivan & Cromwell LLP.

Mr. RUAN graduated from The Hong Kong University of Science and Technology in November 2021 with a master's degree of science, majoring in biotechnology. He graduated from The University of New South Wales in December 2009 with bachelor's degree of laws and bachelor's degree of commerce majoring in finance.

MS. CHEN

Ms. CHEN, aged 29, joined the Company on July 1, 2021 and currently serves as the securities affairs manager of the Company. Ms. CHEN has several years of experience in corporate governance and company secretarial practice. Prior to joining our Group, Ms. CHEN served as the senior manager of capital markets and investor relations at Shanghai Fosun High Technology (Group) Co. Ltd. (上海復星高科技(集團)有限公司), a subsidiary of Fosun International Limited (復星國際有限公司), a company whose shares are listed on the Stock Exchange (stock code: 656), from September 2020 to June 2021. From April 2017 to September 2020, she served as the supervisor of the secretariat to the board at Guangzhou Baiyunshan Pharmaceutical Holdings Co., Ltd. (廣州白雲山醫藥集團股份有限公司), a company whose shares are listed on the Shanghai Stock Exchange (stock code: 600332) and the Stock Exchange (stock code: 874).

Ms. CHEN obtained her bachelor's degree in business administration from The Chinese University of Hong Kong in November 2016 and her master's degree in corporate governance from Hong Kong Metropolitan University in March 2023. She has been an associate member of The Hong Kong Chartered Governance Institute since July 2023.

The Board would like to take this opportunity to express its sincere gratitude to Ms. JI and Ms. CHAU for their valuable contributions to the Company during their respective terms of office and extend its warm welcome to Mr. RUAN and Ms. CHEN on their new appointment.

By order of the Board
Ocumension Therapeutics
Dr. Lian Yong CHEN
Chairman and Non-executive Director

Hong Kong, September 29, 2023

As of the date of this announcement, the Board comprises Mr. Ye LIU and Dr. Zhaopeng HU as executive directors, Dr. Lian Yong CHEN, Dr. Wei LI, Mr. Yanling CAO and Ms. Yumeng WANG as non-executive directors, and Mr. Ting Yuk Anthony WU, Mr. Yiran HUANG and Mr. Zhenyu ZHANG as independent non-executive directors.